Our Work
There’s never been a greater need for an effective antiviral. We have developed a new broad-spectrum antiviral compound that has shown the potential to be effective against a wide range of clinical and priority viruses. We call our compound ‘VTose®’.
Latest News
Kimer Med was awarded a 2021-22 Project Grant from Callaghan Innovation, the New Zealand government’s innovation agency. This funding provides a boost to our ongoing R&D work by reimbursing NZD$150,000 of our eligible expenses over the next two years.
Support Us
Our goal is to end viral disease, and we need your help to achieve it! You can support this critical research by donating and also by spreading the word about what we are doing. Your support is welcome and very much appreciated – and every dollar counts.
We're working on a new broad-spectrum antiviral drug.
Kimer Med is a post-seed biotech start-up, located in Nelson, New Zealand. We’re optimising a new, broad-spectrum antiviral drug. The compound, which we call VTose, is a derivative of DRACO, which was tested and found effective in vitro against 15 different viruses in 11 tissue types, and against Influenza H1N1 in mice.
Antivirals are a vital tool to deal with viral disease
Historically and currently, the harm to human life caused by pathogenic viruses is on an enormous scale! In years gone by, viruses such as smallpox killed hundreds of millions, perhaps over 300 million as late as the 20th century. The polio virus paralysed over 15,000 people annually. The 1918 flu pandemic killed upwards of 100 million.
Read more about our efforts to address this age-old problem.
Read the Latest News and Articles from Kimer Med
More than 3,000 people die every day from liver disease caused by viral hepatitis!
More than 3,000 people die every day from liver disease caused by viral hepatitis, and today (July 28) is World Hepatitis Day. What is World Hepatitis Day? World Hepatitis Day…
Kimer Med Awarded Callaghan Innovation project grant for antiviral development
We are thrilled to receive this significant support in the form of R&D funding, and see it as recognition of the important science that we are undertaking. Media Release -…
Vaccines are only part of the solution to the significant harm caused by viral disease. Here’s why.
There's been a huge amount of interest in and discussion about vaccines over the past couple of years, and more than 66% of the world's population has now received at…
Join the conversation
You can contribute to our efforts to end viral disease. Talk with our co-founders, other professionals and interested parties about the development of our new broad-spectrum antiviral drug.